Skip to content

Study · In vitro (cells) · 2001

6 results

Detailed characterization of neuroprotection by a rescue factor humanin against various Alzheimer's disease-relevant insults.

Hashimoto Y, Niikura T, Ito Y, Sudo H, Hata M, Arakawa E, Abe Y, Kita Y, Nishimoto I

The Journal of neuroscience : the official journal of the Society for Neuroscience1 Dec 2001Cited by 173 (Europe PMC)

PMID11717357 (opens in a new tab)PMCIDPMC6763898 (opens in a new tab)DOI10.1523/jneurosci.21-23-09235.2001 (opens in a new tab)PepBankPUB-11717357
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    Humanin inhibited neurotoxicity caused by other familial Alzheimer's disease genes (A617G-APP, L648P-APP, A246E-PS1, L286V-PS1, C410Y-PS1 and H163R-PS1).

    In plain wordsIn cells, humanin reduced nerve cell toxicity caused by several other Alzheimer's disease gene mutations.

    Peptide
    Humanin
    Outcome
    DecreaseNeurotoxicity by other familial AD genes
    Study

    n: not reported in source

    neuronal cells
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Here we report that HN can also inhibit neurotoxicity by other AD-relevant insults: other familial AD genes (A617G-APP, L648P-APP, A246E-PS1, L286V-PS1, C410Y-PS1, and H163R-PS1), APP stimulation by anti-APP antibody, and other Abeta peptides (Abeta1-42 and Abeta25-35).
  2. 02LabIn vitro (cells)Activity measurement

    Humanin inhibited neurotoxicity caused by APP stimulation with anti-APP antibody.

    In plain wordsIn cells, humanin reduced nerve cell toxicity caused by stimulating the APP protein with an antibody.

    Peptide
    Humanin
    Outcome
    DecreaseNeurotoxicity by APP stimulation with anti-APP antibody
    Study

    n: not reported in source

    neuronal cells
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Here we report that HN can also inhibit neurotoxicity by other AD-relevant insults: other familial AD genes (A617G-APP, L648P-APP, A246E-PS1, L286V-PS1, C410Y-PS1, and H163R-PS1), APP stimulation by anti-APP antibody, and other Abeta peptides (Abeta1-42 and Abeta25-35).
  3. 03LabIn vitro (cells)Activity measurement

    Humanin inhibited neurotoxicity caused by the amyloid-beta peptides Abeta1-42 and Abeta25-35.

    In plain wordsIn cells, humanin reduced nerve cell toxicity caused by two other forms of amyloid-beta.

    Peptide
    Humanin
    Outcome
    DecreaseNeurotoxicity by Abeta1-42 and Abeta25-35
    Study

    n: not reported in source

    neuronal cells
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Here we report that HN can also inhibit neurotoxicity by other AD-relevant insults: other familial AD genes (A617G-APP, L648P-APP, A246E-PS1, L286V-PS1, C410Y-PS1, and H163R-PS1), APP stimulation by anti-APP antibody, and other Abeta peptides (Abeta1-42 and Abeta25-35).
  4. 04LabIn vitro (cells)Activity measurement

    Humanin could not suppress neurotoxicity caused by glutamate or prion fragment.

    In plain wordsIn cells, humanin did not reduce nerve cell toxicity caused by glutamate or by a prion fragment.

    Peptide
    Humanin
    Outcome
    No significant changeNeurotoxicity by glutamate or prion fragment
    Study

    n: not reported in source

    neuronal cells
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The action specificity was further indicated by the finding that HN could not suppress neurotoxicity by glutamate or prion fragment.
  5. 05LabIn vitro (cells)Mechanism

    Cys(8) and Ser(14) were essential for the rescue action of Humanin, and the domain from Pro(3) to Pro(19) was responsible for it.

    In plain wordsIn cells, two amino acids and a middle part of humanin were needed for its protective action.

    Peptide
    Humanin
    Outcome
    Not applicableResidues and domain of HN needed for rescue action
    Study

    n: not reported in source

    neuronal cells
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Against the AD-relevant insults, essential roles of Cys(8) and Ser(14) were commonly indicated, and the domain from Pro(3) to Pro(19) was responsible for the rescue action of HN, in which seven residues turned out to be essential.
  6. 06LabIn vitro (cells)Activity measurement

    S14G Humanin (HNG) abolished cytotoxicity from all tested Alzheimer's disease-relevant insults, whereas activity-dependent neurotrophic factor, IGF-I and basic FGF each abolished Abeta1-43 toxicity but not all of the insults.

    In plain wordsIn cells, a changed form of humanin blocked all tested Alzheimer's-related toxic insults, while three other protective factors did not block all of them.

    Peptide
    Humanin
    Outcome
    DecreaseNeurotoxicity by all tested AD-relevant insults (HNG vs other factors)
    Study

    n: not reported in source

    neuronal cells
    Comparator
    ADNF, IGF-I, bFGF
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Although all of these factors could abolish neurotoxicity by Abeta1-43, only HNG could abolish cytotoxicities by all of them.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.